CHA sent a comment letter to the FDA on draft guidance that recommends how and when manufacturers provide additional information in drug shortage notifications to the agency. Our letter urges the FDA to address the specific challenges facing the pediatric drug supply chain through transparency requirements, developing proactive shortage mitigation plans, and ensuring an accounting of pediatric drugs on the FDA drug shortages list.
CHA Submits Comments on FDA Drug Shortage Guidance
Related Content
CHA Submits Comments in Response to Medicaid Provider Tax Proposed Rule
Provider taxes are important mechanisms used to fund programs and support providers that treat a large volume of Medicaid patients, including children’s hospitals.
The Pharmacy That Keeps Brynn Dancing
The Cincinnati Children’s home care pharmacy is indispensable to children with complex medical conditions.
Children’s Groups Submit Joint Comments on ACA Marketplace Affordability and Integrity Proposed Rule
Insurance coverage for children should ensure access to timely, affordable, high-quality, and age-appropriate health care that meets their unique needs.